<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00369616</url>
  </required_header>
  <id_info>
    <org_study_id>CYT002-NicQb 02</org_study_id>
    <nct_id>NCT00369616</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Nicotine-Qbeta Vaccine in Smokers</brief_title>
  <official_title>Evaluation of Efficacy and Safety of Nicotine-Qbeta (NicQb) Vaccine Versus Placebo in Healthy Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cytos Biotechnology AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cytos Biotechnology AG</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to help smokers quitting by vaccinating them with CYT002-NicQb.&#xD;
      Upon vaccination, the smoker will generate antibodies directed against free nicotine. The&#xD;
      antibodies will bind nicotine and prevent its passage into the brain. The successfully&#xD;
      vaccinated smoker will have no reward effect after smoking, thus braking the vicious circle&#xD;
      of nicotine addiction.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">October 2005</completion_date>
  <primary_completion_date type="Actual">March 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Abstinence from smoking defined as self-reported abstinence and confirmed by measurement of carbon monoxide in exhaled air less than 10ppm</measure>
    <time_frame>Monthly up to month 6, and during follow-up at months 9 and 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity of the vaccine, by measuring specific anti-nicotine IgG antibodies by ELISA</measure>
    <time_frame>Baseline, monthly up to month 6, and months 9 and 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability by recording adverse events, injection site examinations, vital signs, standard clinical laboratory (serum chemistry, hematology)</measure>
    <time_frame>Baseline, and at various times up to month 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Craving and withdrawal symptoms by Questionnaire on Smoking Urges and Wisconsin Withdrawal Scale</measure>
    <time_frame>Baseline, monthly up to month 6</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">341</enrollment>
  <condition>Smokers</condition>
  <arm_group>
    <arm_group_label>NicQb vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo vaccine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CYT002-NicQb</intervention_name>
    <arm_group_label>NicQb vaccine</arm_group_label>
    <arm_group_label>Placebo vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Age 18 to 70 years&#xD;
&#xD;
          -  Smokers: &gt; 10 and ≤ 40 cigarettes per day and smoking history of more than 3 years&#xD;
&#xD;
          -  Fageström Test for Nicotine Dependence (FTND) score ≥ 5&#xD;
&#xD;
          -  Female participant must meet one of the following criteria: a) no reproductive&#xD;
             potential due to menopause, hysterectomy, bilateral oophorectomy, or tubal ligation;&#xD;
             b) agrees to consistently practice an effective and accepted method of contraception&#xD;
             throughout the duration of the study and for 12 additional months after the last&#xD;
             immunization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
&#xD;
          -  History of severe allergy or immunological disorders&#xD;
&#xD;
          -  Blood donation within previous 30 days&#xD;
&#xD;
          -  Surgery within previous 30 days&#xD;
&#xD;
          -  Use of investigational drugs within previous 60 days&#xD;
&#xD;
          -  Significant cardiovascular disease:&#xD;
&#xD;
               -  angina pectoris&#xD;
&#xD;
               -  congestive heart failure&#xD;
&#xD;
               -  clinically significant murmurs&#xD;
&#xD;
               -  previous angioplasty or coronary artery bypass surgery&#xD;
&#xD;
          -  Active infectious disease:&#xD;
&#xD;
               -  WBC &gt; 12 000 cells/µL&#xD;
&#xD;
               -  Seropositivity for Hepatitis B and C&#xD;
&#xD;
               -  History of risk behavior to acquire HIV&#xD;
&#xD;
          -  Significant hepatic disease&#xD;
&#xD;
          -  Significant renal disease&#xD;
&#xD;
          -  Significant hematological disorder&#xD;
&#xD;
          -  Significant pulmonary disease&#xD;
&#xD;
          -  History of malignancy&#xD;
&#xD;
          -  Autoimmune disease&#xD;
&#xD;
          -  Organic neurological disorder or significant psychiatric disorder&#xD;
&#xD;
          -  Use of psychoactive drug within one month before enrolment&#xD;
&#xD;
          -  Abuse of drugs or alcohol&#xD;
&#xD;
          -  Subjects using any concomitant medications due to chronic illness which bears a high&#xD;
             risk of fluctuation in disease activity or exacerbations during a 12-months period&#xD;
             such as coronary heart disease, asthma, severe COPD, chronic rheumatoid disease,&#xD;
             diabetes, etc. should be excluded.&#xD;
&#xD;
          -  Obesity: BMI &gt; 35 kg/m2&#xD;
&#xD;
          -  Use of concomitant nicotine replacement treatment (NRT) at screening or visit 1&#xD;
&#xD;
          -  Any planned surgical intervention during the study period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Jacques Cornuz, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Medicine; University Hospital Lausanne, Switzeland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Cerny, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine, Kantonsspital St. Gallen, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Felix Jungi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine, Kantonsspital St. Gallen, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karl Klingler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lung Center Hirslanden, Zuerich, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Lausanne (CHUV)</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lungenzentrum Hirslandenklinik Zuerich</name>
      <address>
        <city>Zuerich</city>
        <zip>8029</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2008</verification_date>
  <study_first_submitted>August 25, 2006</study_first_submitted>
  <study_first_submitted_qc>August 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2006</study_first_posted>
  <last_update_submitted>November 11, 2010</last_update_submitted>
  <last_update_submitted_qc>November 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2010</last_update_posted>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

